Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ICT 107

Next Previous
Drug Profile

ICT 107

Alternative Names: Cancer vaccine - ImmunoCellular Therapeutics; Dendritic cell vaccines - ImmunoCellular Therapeutics; ICT-107

Latest Information Update: 03 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No
  • Available For Licensing Yes - Glioblastoma

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 03 Sep 2021 Discontinued - Phase-III for Glioblastoma (Combination therapy, First-line therapy) in USA, Austria, Canada, Netherlands, Germany, Spain (Intradermal) (ImmunoCellular Therapeutics website, September 2021)
  • 08 May 2019 ImmunoCellular Therapeutics and Unknown company entered into a asset purchase agreement for ICT 107, ICT 140, ICT 121 and stem-to-T-cell research programme preclinical asset
  • 21 Jun 2017 ICT 107 is available for licensing as of 21 Jun 2017. www.imuc.com

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top